Aim for a deep molecular response—MR4.51

With TASIGNA, significantly more patients reached MR4.5 by 3 years and by 5 years, vs imatinib.1

 

 

 

 

Patients reached MR4.5 more than 1 year faster with TASIGNA, vs imatinib2

Nearly twice as many newly diagnosed patients reached MR4.5 more than 1 year faster with TASIGNA than with imatinib2  

Median time to achieve MR4.5

 

 

 

 

Patients achieved deeper responses faster with TASIGNA than with imatinib2 

Cumulative Incidence of MR4.5

 

 

 

 

Across Sokal risk groups, TASIGNA achieved higher rates of MR4.5 than imatinib3

In ENESTnd, TASIGNA was superior to imatinib in all Sokal risk scores3  

Percentage of patients achieving MR4.5 by 5 years

Percentage of patients with MMR by 1 year in ENESTnd1

Percentage of patients with MMR by 1 year in ENESTnd

 

 

 

 

Adverse events occurring at ≥10% in patients on TASIGNA: rash, pruritus, dry skin, headache, nausea, fatigue, alopecia, myalgia, constipation, and upper abdominal pain. Most were mild to moderate in severity (grade 1/2).1

ENESTnd is a randomized, controlled, open-label, international, multicenter trial of 846 patients with newly diagnosed Ph+ CML-CP. Patients were randomized to 1 of 2 TASIGNA arms or to imatinib. The primary endpoint was MMR at 12 months.1

  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; May 2017.
  2. Larson RA, et al. Blood. 2014;124. Abstract 4541.
  3. Hochhaus A, et al. Leukemia. 2016;30(5):1044-1054.